708
to socio-economic factors in some developing Asian countries. Japan, with an
advanced healthcare system and a prominent position of research activity in genomic
medicine, has good prospects for introduction of personalized medicine. China,
which is making considerable advances in new biotechnologies and applying them
in genomics and sequencing, has the facilities for developing personalized medi-
cine. The US will be the fi rst country to adopt personalized medicine on a large
scale as the US healthcare system has undergone reforms referred to as “Obamacare”
or universal healthcare introduced in 2013.
References
Agboola SO, Ball M, Kvedar JC, Jethwani K. The future of Connected Health in preventive medi-
cine. QJM. 2013;106:791–4.
Anonymous. Personalised medicines: hopes and realities. London: The Royal Society; 2005.
Ball MP, Thakuria JV, Zaranek AW, et al. A public resource facilitating clinical use of genomes.
Proc Natl Acad Sci U S A. 2012;109:11920–7.
Caulfi eld BM, Donnelly SC. What is Connected Health and why will it change your practice?
QJM. 2013;106:703–7.
Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine?
NEJM. 2009;360:1925–7.
Goldstein JI, Fredrik Jarskog L, Hilliard C, et al. Clozapine-induced agranulocytosis is associated
with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757.
Jain KK. Personalized medicine. Waltham: Decision Resources Inc; 1998.
Jain KK. A critical review of the Royal Society’s report on personalized medicine (editorial). Drug
Discov Today. 2006;11:573–5.
Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medi-
cine: how can we accelerate the appropriate integration of human genome discoveries into
health care and disease prevention? Genet Med. 2007;9:665–74.
McClellan J, King MC. Genetic heterogeneity in human disease. Cell. 2010;141:210–7.
Regierer B, Zazzu V, Sudbrak R, et al. Future of medicine: models in predictive diagnostics and
personalized medicine. Adv Biochem Eng Biotechnol. 2013;133:15–33.
Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult
diseases: a systematic review. JAMA. 2008;299:1320–34.
Vizirianakis IS. Clinical translation of genotyping and haplotyping data: implementation of in vivo
pharmacology experience leading drug prescription to pharmacotyping. Clin Pharmacokinet.
2007;46:807–24.
Vizirianakis IS. Nanomedicine and personalized medicine toward the application of pharmacotyp-
ing in clinical practice to improve drug-delivery outcomes. Nanomedicine. 2011;7:11–7.
24 Future of Personalized Medicine